Indivior Pharmaceuticals, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 38/100
What the filing says
Indivior UK Ltd and Reckitt Benckiser Healthcare (UK) Limited executed a deed dated 19 August 2026 to terminate their copacker supply agreement effective 15 January 2027 (moved forward from 31 December 2027). Indivior must pay Reckitt unspecified amounts for under-absorption costs, asset investment recovery, equipment removal, redundancy, and incentive costs—most dollar figures are redacted [***], preventing full quantification of financial impact.
Why this rating
Supply chain disruption with cost obligations, but lack of disclosed amounts limits full assessment. Represents meaningful operational/financial event for ~$1.8B company, though redactions obscure magnitude.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.